2024
Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)
Ali A, Ahmed N, Kim S, Bye M, Mirza S, Sieg A, Strouse C, Nadiminti K, Pophali P, Kamble R, Gowda L, Turtle C, Phillips C, Pasquini M, Ahmed S, Ganguly S, Moskop A. Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL). Blood 2024, 144: 71. DOI: 10.1182/blood-2024-200269.Peer-Reviewed Original ResearchCD19 chimeric antigen receptorProgression-free survivalOverall response rateProlonged cytopeniasOverall survivalLiso-celTisa-celFludarabine groupLymphodepleting chemotherapyLD regimenT cellsCAR T cell productCD19 CAR-T therapyMultivariate analysisCD19 CAR-T cellsProbability of overall survivalLower CrsLD regimensCAR-T cellsT-cell therapyChimeric antigen receptorCAR-T therapyMedian follow-upT cell expansionT cell production
2023
Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Sidana S, Ahmed N, Akhtar O, Heim M, Brazauskas R, Hansen D, Ferreri C, Freeman C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison M, Kitali A, Mirza S, Patel J, Patwardhan P, Usmani S, Patel K, Ganguly S, Pasquini M. Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma. Blood 2023, 142: 1027. DOI: 10.1182/blood-2023-181762.Peer-Reviewed Original ResearchCAR T-cell therapyRefractory multiple myelomaCytokine release syndromeHigh-risk cytogeneticsProgression-free survivalLow performance statusReal-world populationExtramedullary diseasePerformance statusClinical trialsResponse rateCell therapyMultivariate analysisOverall survivalMedian timeMultiple myelomaRelapsed/Refractory Multiple MyelomaTreatment of RRMMCAR T-cell doseISS stage III diseasePresence of EMDGood partial response rateLarge real-world studyPre-treated populationComplete response rate
2021
Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study
Byrne M, Kurian T, Patel D, Tamari R, Hong S, Abdelhakim H, Klein V, Rojas P, Madhavan R, Kent A, Logan A, Lee C, Husnain M, Manning B, Tschernia N, Dias A, Margalski D, Goldenson B, Byrne N, Chen H, Petrova-Drus K, Sengsayadeth S, Goodman A, Howard D, Wood W, Gill S, Jimenez A, Gutman J, Gowda L, Metheny L, Bhatnagar B, Hamilton B, Mishra A, Savona M. Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study. Blood 2021, 138: 2922. DOI: 10.1182/blood-2021-154151.Peer-Reviewed Original ResearchNon-relapse mortalityMDS/AMLChronic GVHDPost-HCT mortalityPost-HCT relapseOverall survivalRelapse/progressionShorter overall survivalBM chimerismComplex karyotypeImproved OSMyeloablative conditioningHigher KPSMultivariate analysisSecondary MDS/AMLAdvisory CommitteeLarge multi-institutional cohortMDS/AML patientsMulti-center collaborative studyLow NRM ratePost-HCT outcomesAllogeneic HCT recipientsSpeakers bureauYear overall survivalInferior overall survival